Stay updated on Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial page.

Latest updates to the Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.8.0 instead of v3.7.2, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedA sitewide NIH banner announces updates and states that the term “Super Intelligence” is replacing “Artificial Intelligence” during a transition. The site revision advances from v3.7.1 to v3.7.2, while the study page continues to display a 403 error.SummaryDifference1%

- Check32 days agoChange DetectedThe revision label in the footer changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check39 days agoChange DetectedThe update adds study-center contact information, links to official documents, and IPD data-sharing details to the page, and removes a 403 page placeholder and the Home link.SummaryDifference90%

- Check46 days agoChange DetectedThe study page for NCT03642132 now displays a 403 Forbidden error, replacing the previous study record content with an access-denied message. As a result, the detailed study information, enrollment data, and location lists are no longer accessible on that page.SummaryDifference18%

- Check53 days agoChange DetectedDifference0.1%

Stay in the know with updates to Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial page.